Search
for
Sort by
Research 871–900 of 1000+
- Supplements That May Counteract Side Effects from Conventional Cancer Therapies
- Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
- Genetic analysis of the role of androgen metabolism in the pathogenesis of prostate cancer
- Certain Cancer Myths Endure, with Impact on Treatment, Prevention, Screening
- Oral contraceptives and risk of breast cancer in women aged 20–54 years
- Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
- Androgenetic Alopecia and Thyroid Cancer: Coincidence or More?
- Faculty Opinions recommendation of Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
- 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
- 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
- Selenium for preventing cancer
- Keratins in health and cancer: more than mere epithelial cell markers
- Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
- Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
- Tracing the cellular origin of cancer
- Hair and cancer chemotherapy: consequences and nursing care - a literature study
- Risk factors for prostate cancer: a case-control study in Greece
- Cutaneous toxicities of cancer therapy
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Selenium for preventing cancer
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt
- Nonmelanoma skin cancer treated with electronic brachytherapy: Results at 1 year
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study
- Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study
- A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment
- 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia
- Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling
- Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate